DLL3 and small cell lung carcinoma: Delta-like protein 3 (DLL3)-targeted ADC rovalpituzumab tesirine (Rova-T) was initially tested in small cell lung cancer (SCLC) with some encouraging results, although randomized pivotal trials failed to demonstrate a survival benefit versus standard of care in pretreated patients and the development of this drug was halted [190,191].